OSR Health, Inc. has made a significant update to its financial strategy by amending its Global Exclusive License Agreement with BCM Europe AG. This amendment introduces a Convertible Note Option, allowing OSR Health to convert its existing equity option into convertible notes. This move aims to enhance the company's financial flexibility, especially in light of recent challenges.
The amendment was executed on October 15, 2026, and follows the company's previous agreement with BCM Europe AG, effective April 29, 2026. Under the original agreement, OSR Health held a put option to require BCM Europe to purchase up to $15 million of its common stock. The new amendment adds provisions that allow OSR Health to change the unexercised equity option into a Convertible Note Option.
OSR Health is a company focused on surgical and medical instruments and apparatus, as indicated by its Standard Industrial Classification (SIC) code of 3841. The company operates under the ticker symbols OSRH and OSRHW on the OTC markets. This amendment reflects OSR Health's ongoing efforts to navigate the complexities of the medical instruments industry.
According to the filing, the amendment acknowledges a material subsequent development affecting the settlement of the equity option due to a delisting determination issued by the Nasdaq Staff on August 19, 2026. This determination has prompted OSR Health to explore alternative financial arrangements to ensure its operational stability.
The Convertible Note Option allows OSR Health to issue convertible notes in an aggregate principal amount of up to $15 million. These notes will be issued in four tranches, with fixed conversion prices set at approximately $2.00, $3.00, $4.00, and $5.00 per share. If the minimum price on the date of the purchase commitment exceeds the conversion price of any tranche, that tranche's conversion price will adjust to the minimum price.
This strategic shift may have implications for OSR Health’s stakeholders, including investors and partners, as it seeks to maintain its financial health amidst industry challenges. The amendment also highlights the competitive landscape in the surgical and medical instruments sector, where companies may need to adopt similar financial strategies to adapt to changing market conditions.
Looking ahead, further developments regarding this amendment and its impact on OSR Health's operations are anticipated. The filing does not specify what happens next, but the company’s proactive approach suggests it is preparing for potential market fluctuations.
Details regarding the full text of the amendment can be found in Exhibit 10.1 of the filing, which is accessible through the SEC's website.